Crystalline forms of N- [3-fluoro-4-({6-(methyloxy)-7-[(3-morph olin-4-ylpropyl)oxy] - quinolin4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cycl opropane-1, 1-dicarboxamide

Details for Australian Patent Application No. 2010274012 (hide)

Owner Exelixis, Inc.

Inventors Cannon, Hilary; Igo, David; Tran, Tri

Agent A J Park

Pub. Number AU-A-2010274012

PCT Pub. Number WO2011/009095

Priority 61/226,509 17.07.09 US

Filing date 16 July 2010

Wipo publication date 20 January 2011

International Classifications

C07D 215/20 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

A61K 31/47 (2006.01) - Quinolines

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

9 February 2012 PCT application entered the National Phase

  PCT publication WO2011/009095 Priority application(s): WO2011/009095

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010274030-Treating patients with intravenous ibuprofen

2010274011-Leveling devices and methods